Collegium Patent-Cliff Exposure & CMS Drug Spending Portfolio

Collegium (US): 3 reconciled FDA prescription therapies (32.1% 2025 to 2030 cliff risk), $383.7M 2024 CMS Part D & Medicaid spend, and 42 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure32.1%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$383.7M
2024 Medicare Part D Spend$336.6M
2024 Medicaid Spend$47.1M
California HCAI SB 17 Filings42 WAC filings (max 38.9% 2-yr change)